Complete response with combined sonidegib and pembrolizumab in synchronous advanced basal cell carcinoma and metastatic cutaneous squamous cell carcinoma: A case report

Abstract

Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most common skin cancers. While most cases are managed with local therapies, advanced disease may require systemic treatment. Hedgehog pathway inhibitors are standard for advanced BCC, whereas PD-1 inhibitors are effective in cSCC. However, no established strategy exists for synchronous advanced BCC and cSCC. We report a case of a patient with synchronous locally advanced BCC and metastatic cSCC treated with combined pembrolizumab and sonidegib, achieving a complete clinical and metabolic response. This case highlights a potential therapeutic approach, warranting further investigation to confirm its safety and efficacy.